Erratum
After publication of the original article [1], an error was noticed within the title: acronym “REBECCA” was erroneously written as “REBACCA”. The original article has now been updated with the correct title which can also be found above. The publisher would like to apologise for this error and for any inconvenience this may have caused.
Footnotes
The online version of the original article can be found under doi:10.1186/s12885-016-2440-9.
References
- 1.Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16:412. doi: 10.1186/s12885-016-2440-9. [DOI] [PMC free article] [PubMed] [Google Scholar]